Cannabis Science Inc.
Cannabis Science Inc.
Home
About Us
Corporate Overview
Mission Statement
Cannabis Science Team
Careers & Corporate Culture
iCannabinoid
Join Now!
R&D
The Science of Cannabinoids
CBIS Cannabinoid Research
Critical Ailments
COLLABORATIONS & PROJECTS
CBIS Medical Consortium
Global Economic Development
Pan African A & C University
African Economic Initiative
American States University
North American Economic Initiative
Dana-Farber
CFA
Stellenbosch University
CBIS Bottle It
Products & Pharmacies
Products
Order Online
Pharmacies
Investors
CBIS Current Share Structure
SEC Filings
Media
CBIS News Releases
CBIS In The News
CBIS Events
Contact
latest Articles
Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth
Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements
Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions
Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally
Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations
CBIS LATEST NEWS.
Home
2018
2018
-
2017
-
2016
-
2015
-
2014
-
2013
-
2012
-
2011
-
2010
-
2009
Warning
: Creating default object from empty value in
/home/cannabisscience/public_html/plugins/system/t3/base-bs3/html/com_content/category/default_articles.php
on line
17
Title
Published Date
Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth
21-10-19
Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements
06-09-19
Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions
28-08-19
Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally
15-08-19
Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations
05-08-19
Cannabis Science, Inc. Successfully Completes Lab Testing for Its Proprietary, Short-Time Vacuum Distillation Process for Distribution of Purified High CBDA and CBD Water-Soluble Powders and Extracts Internationally
26-07-19
Mr. Raymond C. Dabney Prepares Cannabis Science for the Next Level With Key Acquisitions Negotiated and Planned Mergers, a New Branding Splash, and a Black-Tie Dinner Awards Gala for the Ages
08-07-19
Cannabis Science Propels Cancer Clinical Trials, Appoints Cellular Cancer Specialist Dr. Sulma Mohammed, Professor of Cancer Biology, Purdue University, to the Company’s Scientific Advisory Board
03-06-19
GHC Summit at Harvard Medical School Announces Cannabis Science as Industry Partner in the Launch of the International Phytomedicines Institute at Harvard Medical Schoo
31-05-19
Cannabis Science Set to Participate in the Premier Event Focused on High-Impact Global Collaborations; The Global Health Catalyst Summit at Harvard Medical School Starts Today
24-05-19
Start
Prev
1
2
3
4
5
6
Next
End